| Davis, Lori Lynne |
VA-BRAVE, NCT04375033: A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder |
|
|
| Recruiting | 4 | 952 | US | Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine | VA Office of Research and Development | Opioid Use Disorder | 09/28 | 05/29 | | |
NCT04961190: A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD |
|
|
| Recruiting | 4 | 300 | US | Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR, Pharmacotherapy with Paxil or Effexor XR | University of Pennsylvania, Patient-Centered Outcomes Research Institute, Corporal Michael J. Crescenz VA Medical Center, Coatesville VA Medical Center, Milwaukee VA Medical Center, North Texas Veterans Healthcare System, San Diego Veterans Healthcare System, VA Palo Alto Health Care System, Birmingham VA Health Care System | Posttraumatic Stress Disorder | 07/26 | 07/26 | | |
IMPACT, NCT05776056: Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints |
|
|
| Recruiting | 4 | 70 | US | Methylphenidate, Ritalin, Placebo | VA Office of Research and Development | Posttraumatic Stress Disorder (PTSD) | 07/26 | 03/27 | | |
| Withdrawn | 4 | 940 | US | Esketamine, Spravato (for depression), Ketanest (for anesthesia), Aripiprazole, Abilify, Aristada | VA Office of Research and Development | Depressive Disorder, Major | 10/23 | 10/23 | | |
NCT03852628: Kappa Opioid Receptor Antagonism for the Tx of AUD and Comorbid PTSD |
|
|
| Terminated | 2 | 69 | US | 2mg Buprenex and 380mg Vivitrol, 2mg Buprenex (SL, qd) and 380mg Vivitrol (IM, q4weeks), 2mg BUP/NLTRX, Placebo (SL pill qd, IM injection q4weeks), Placebo | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, United States Department of Defense, RTI International | Post Traumatic Stress Disorder, Alcohol Abuse | 05/22 | 01/23 | | |
| Active, not recruiting | N/A | 100 | US | Standard Vocational Rehabilitation, VRP, Supportive Employment, SE | Tuscaloosa Research & Education Advancement Corporation | PTSD | 06/10 | 05/14 | | |
Pan-ACT, NCT05433662: Telehealth Acceptance and Commitment Therapy for Older Veterans Experiencing Pandemic-Related Stress |
|
|
| Completed | N/A | 24 | US | Pandemic Acceptance and Commitment Therapy (Pan-ACT), Acceptance and Commitment Therapy (ACT); ACT for Older Adults; The Third ACT | VA Office of Research and Development, University of Alabama, Tuscaloosa | Psychological Stress | 12/24 | 01/25 | | |
| Recruiting | N/A | 240 | US | Minds and Mentors, Twelve Step Intervention Group | University of Alabama, Tuscaloosa, University of Alabama at Birmingham, Tuscaloosa Veterans Affairs Medical Center, Pathway Healthcare, LLC | Opioid Use Disorder, Substance Use Disorders, Medication Assisted Treatment | 08/24 | 08/24 | | |
NCT06770998: A Study of a Novel EEG Neurofeedback System for PTSD Treatment |
|
|
| Not yet recruiting | N/A | 250 | US | EEG-neurofeedback training, Prism training, amyg-EFP training, active Prism training, Sham training, sham Prism training | Foundation for Atlanta Veterans Education and Research, Inc., GrayMatters Health Ltd., Rochester Institute of Technology, New York University Grossman School of Medicine, Atlanta VA Medical Center, Birmingham VA Health Care System, Ralph H. Johnson VA Medical Center, VA Boston Healthcare System, CTP Inc, BioStats Statistical Consulting Ltd, ShareCRF, United States Department of Defense | Stress Disorders, Post-Traumatic | 06/27 | 08/27 | | |
| Recruiting | N/A | 120 | US | Treatment As Usual Vocational Rehabilitation (TAU-VR), Individual Placement and Support (IPS) | VA Office of Research and Development | Veterans With Opioid Use Disorder | 08/26 | 09/26 | | |
